Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by HighSkies2019on May 25, 2020 5:09pm
204 Views
Post# 31070562

Let's Hope The Price Is Right !

Let's Hope The Price Is Right !Jmo ... I think Rob was looking to partner up...he did say awhile back at the beginning that he intended to make Kly one of the biggest players in the pharmaceutical industry .. maybe too much baggage with debt and relations tied up in other companies.. maybe Rob was asking too much...and or but interest for the GVHD only was what the other parties sought after.. no one wanted to partner so Rob had to take a buyout ... call me crazy but I still think that possible chance still like GW to buy it outright .... they already have the almost twin of.. their already approved FDA epilepsy drug ... this covid play surfaced and Rob saw another opportunity to continue with Kly..Covid is the play for stks today and makes sense in today's global news... the funds of the GVHD sale will pay of any outstanding debt and Kly shareholders will see an increase in sp ... we are now bounced to June 30 to see if we will see a sale and the value ... I think that there is a definite sale ... not a pumper ... I am in low on over quarter million stocks... could brake even with a bit xtra today.. But there is more goodies in the cookie jar so I will hang tight till end of June..again jmo ..glta
<< Previous
Bullboard Posts
Next >>